WO2016003327A9 - Применение 3-(3-[1,2,4]-триазоло)-оксатриазолий-5-олата для лечения сексуальных расстройств - Google Patents

Применение 3-(3-[1,2,4]-триазоло)-оксатриазолий-5-олата для лечения сексуальных расстройств Download PDF

Info

Publication number
WO2016003327A9
WO2016003327A9 PCT/RU2015/000413 RU2015000413W WO2016003327A9 WO 2016003327 A9 WO2016003327 A9 WO 2016003327A9 RU 2015000413 W RU2015000413 W RU 2015000413W WO 2016003327 A9 WO2016003327 A9 WO 2016003327A9
Authority
WO
WIPO (PCT)
Prior art keywords
oxatriazolium
olate
triazolo
sexual disorders
treating sexual
Prior art date
Application number
PCT/RU2015/000413
Other languages
English (en)
French (fr)
Other versions
WO2016003327A1 (ru
Inventor
Юрий Владимирович ХМЕЛЬЩИКОВ
Дмитрий Сергеевич НОСКОВ
Original Assignee
Общество С Ограниченной Ответственностью "Консорциум-Пик"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Консорциум-Пик" filed Critical Общество С Ограниченной Ответственностью "Консорциум-Пик"
Priority to PL15815425T priority Critical patent/PL3165223T3/pl
Priority to EP15815425.2A priority patent/EP3165223B1/en
Priority to EA201700038A priority patent/EA032337B1/ru
Priority to ES15815425T priority patent/ES2747995T3/es
Priority to US15/323,567 priority patent/US9795593B2/en
Publication of WO2016003327A1 publication Critical patent/WO2016003327A1/ru
Publication of WO2016003327A9 publication Critical patent/WO2016003327A9/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Применение 3-(3-[1,2,4]-триазоло)-оксатриазолий-5-олата для лечения сексуальных расстройств Изобретение относится к химико-фармацевтической промышленности, в частности, к созданию нового средства для лечения сексуальных расстройств, и может быть использовано в биохимии, физиологии и медицине.
PCT/RU2015/000413 2014-07-04 2015-07-01 Применение 3-(3-[1,2,4]-триазоло)-оксатриазолий-5-олата для лечения сексуальных расстройств WO2016003327A1 (ru)

Priority Applications (5)

Application Number Priority Date Filing Date Title
PL15815425T PL3165223T3 (pl) 2014-07-04 2015-07-01 Zastosowanie 3-(3-[1,2,4]-triazolo)-oksatriazolium-5-olatu do leczenia zaburzeń seksualnych
EP15815425.2A EP3165223B1 (en) 2014-07-04 2015-07-01 Use of 3-(3-[1,2,4]-triazolo)-oxatriazolium-5-olate for treating sexual disorders
EA201700038A EA032337B1 (ru) 2014-07-04 2015-07-01 Применение 3-(3-[1,2,4]-триазоло)оксатриазолий-5-олата для лечения сексуальных расстройств
ES15815425T ES2747995T3 (es) 2014-07-04 2015-07-01 Uso de 3-(3-[1,2,4]-triazolo)-oxatriazolio-5-olato para tratar trastornos sexuales
US15/323,567 US9795593B2 (en) 2014-07-04 2015-07-01 Use of 3-(3-[1,2,4]-triazolo)-oxatriazolium-5-olate for treating sexual disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2014127279/15A RU2600845C2 (ru) 2014-07-04 2014-07-04 Применение производных оксатриазолий-5-олата для лечения сексуальных расстройств
RU2014127279 2014-07-04

Publications (2)

Publication Number Publication Date
WO2016003327A1 WO2016003327A1 (ru) 2016-01-07
WO2016003327A9 true WO2016003327A9 (ru) 2016-02-11

Family

ID=55019709

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2015/000413 WO2016003327A1 (ru) 2014-07-04 2015-07-01 Применение 3-(3-[1,2,4]-триазоло)-оксатриазолий-5-олата для лечения сексуальных расстройств

Country Status (7)

Country Link
US (1) US9795593B2 (ru)
EP (1) EP3165223B1 (ru)
EA (1) EA032337B1 (ru)
ES (1) ES2747995T3 (ru)
PL (1) PL3165223T3 (ru)
RU (1) RU2600845C2 (ru)
WO (1) WO2016003327A1 (ru)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3911668A1 (de) 1989-04-10 1990-10-11 Cassella Ag Substituierte 1.2.3.4-oxatriazolium-5-olate, verfahren zu ihrer herstellung und ihre verwendung
DE10222550A1 (de) 2002-05-17 2003-11-27 Bayer Ag Substituierte Benzyl-pyrazolopyridine
WO2005023189A2 (en) 2003-09-03 2005-03-17 Pharmacia Corporation Method of cox-2 selective inhibitor and nitric oxide-donating agent
AU2005306629A1 (en) 2004-11-15 2006-05-26 Nicox S.A. Diuretic compounds comprising heterocyclic nitric oxide donor groups, compositions and methods of use
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
WO2008087177A1 (en) 2007-01-18 2008-07-24 Neurosearch A/S Novel semicarbazide and carbonylhydrazide derivatives useful as potassium channel modulators
RU2351328C1 (ru) * 2007-08-02 2009-04-10 Общество с ограниченной ответственнотью "Консорциум-ПИК" (ООО "Консорциум-ПИК") Гипотензивное средство 3-(3-[1,2,4]-триазоло)-оксатриазолий-5-олата длительного действия
WO2011161655A1 (en) 2010-06-25 2011-12-29 Horphag Research (Ip) Pre Ltd Composition for improving sexual wellness
KR101189108B1 (ko) 2011-12-29 2012-10-10 재단법인 전라남도생물산업진흥재단 황칠나무 추출물을 포함하는 남성 성기능 개선용 조성물

Also Published As

Publication number Publication date
EA201700038A1 (ru) 2017-07-31
EA032337B1 (ru) 2019-05-31
US20170202809A1 (en) 2017-07-20
RU2014127279A (ru) 2016-01-27
EP3165223A1 (en) 2017-05-10
PL3165223T3 (pl) 2020-01-31
EP3165223B1 (en) 2019-06-26
US9795593B2 (en) 2017-10-24
ES2747995T3 (es) 2020-03-12
RU2600845C2 (ru) 2016-10-27
WO2016003327A1 (ru) 2016-01-07
EP3165223A4 (en) 2017-07-26

Similar Documents

Publication Publication Date Title
IL256085B (en) A substituted derivative of cholanoic acid, a pharmaceutical composition comprising it and the substituted derivative for use in treatment
IL255509B (en) Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases
HRP20210518T1 (hr) Derivati 2,4-tiazolidindiona, namijenjeni liječenju poremećaja središnjeg živčanog sustava
FI3674298T3 (fi) Substituoituja indatsoleja, menetelmä niiden valmistamiseksi, niitä sisältäviä farmaseuttisia valmisteita sekä niiden käyttö lääkkeiden valmistukseen
IL258471A (en) 11,13-modified saxitoxins for the treatment of pain
WO2015077503A8 (en) Autotaxin inhibitor compounds
EP3328864A4 (en) COMPOUNDS AND THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF SOCIAL DISORDERS AND ADDICTION-RELATED DISORDERS
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
IL269894B (en) Small organic molecules for use in the treatment of neuroinflammatory diseases
EP3549582A3 (en) Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
IL280389A (en) Bile acid receptor modulators conjugated to G.1 protein and methods of using them
IL251840A0 (en) Use of femiroplast in the treatment of severe asthma
PL3157918T3 (pl) Pochodne 2-arylo-4-hydroksy-1,3-tiazolowe użyteczne jako inhibitory TRPM8 w leczeniu nerwobólu, bólu, POChP i astmy
WO2016144706A3 (en) Autotaxin inhibitor compounds and uses thereof
WO2016144704A3 (en) Heterocyclic autotaxin inhibitor compounds
WO2016082807A3 (zh) 伊曲康唑的新用途
WO2016003327A9 (ru) Применение 3-(3-[1,2,4]-триазоло)-оксатриазолий-5-олата для лечения сексуальных расстройств
WO2016073652A8 (en) Iminosugars useful for the treatment of viral diseases
GB201608841D0 (en) Use of neurotoxin in the treatment of overweight, including obesity
AU2015902659A0 (en) Therapeutic compounds and compositions for treating social disorders and substance use disorders
MX2015007748A (es) Proceso de obtencion y composicion farmaceutica deesomeprazol magnesio dihidratado en capsula para el tratamiento de padecimientos gastricos.
WO2016005823A3 (en) Compositions for treating skin conditions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15815425

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015815425

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015815425

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 201700038

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 15323567

Country of ref document: US